Pathologists need not include different subtypes of primary CIS in their report as there is no difference in patient outcomes. It is important to recognize all different subtypes as CIS for best patient treatment.
Different subtypes of carcinoma in situ of the bladder do not have a different prognosis | DocGuide
Different subtypes of carcinoma in situ of the bladder do not have a different prognosis | DocGuide
Pathologists need not include different subtypes of primary CIS in their report as there is no difference in patient outcomes. It is important to recognize all different subtypes as CIS for best patient treatment.
Pathologists need not include different subtypes of primary CIS in their report as there is no difference in patient outcomes. It is important to recognize all different subtypes as CIS for best patient treatment.
Přihlásit se k odběru:
Komentáře k příspěvku (Atom)
-
Onkozpravodaj - Neoadjuvantní dose‑dense chemoterapie režimem M‑VAC s podporou růstovými faktory u pacientů s invazivním uroteliálním karc...
-
článek zde Shan L, Liu W, Zhan Y. Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR in...
Žádné komentáře:
Okomentovat